Company Encyclopedia
View More
name
Dechra Pharmaceuticals PLC
DPH.UK
News
View More

Intervacc And Dechra Extend Distribution Agreement

Intervacc AB :INTERVACC AND DECHRA EXTEND DISTRIBUTION AGREEMENT FOR INTERVACC'S EQUINE STRANGLES VACCINE STRANGVAC BY TWO YEARSEXTENSION EFFECTIVE APRIL 2026, COVERS STRANGVAC VACCINE

Reuters·
UK
DPH
0.00%
Reuters·
UK
DPH
0.00%

Intervacc's distribution partner Dechra launches Strangvac in Spain, Portugal and Slovenia

Intervacc AB announces that its distribution partner, Dechra Pharmaceuticals, is launching the Strangvac vaccine in Spain, Portugal, and Slovenia. This vaccine, which protects against the contagious equine disease strangles, is already approved in the EU and has been launched in several other European countries. CEO Jonas Sohlman emphasizes the importance of this launch for animal health in the equine industry. Strangvac is developed using innovative technology and is part of Intervacc's commitment to improving animal health across Europe.

Reuters·
UK
DPH
0.00%
Reuters·
UK
DPH
0.00%

12:44 ET Ahead of Take Your Dog to Work Day, HABRI and Dechra Partner to Strengthen the Human-Animal Bond

The Human Animal Bond Research Institute (HABRI) and Dechra have partnered to promote the human-animal bond ahead of "Take Your Dog to Work Day." This collaboration aims to enhance awareness of the benefits of pet-inclusive workplaces, highlighting research that shows pets can reduce stress and improve job satisfaction. Dechra's expertise in veterinary care will support outreach and education efforts, emphasizing the importance of the bond for mental health and wellness. Both organizations are committed to advancing research and advocacy for the human-animal bond.

prnewswire·
UK
DPH
0.00%
prnewswire·
UK
DPH
0.00%

Intervacc's distribution partner Dechra launches Strangvac in Finland

Intervacc AB announces that its distribution partner, Dechra Pharmaceuticals PLC, will launch the Strangvac vaccine in Finland. This follows an extended collaboration, allowing Dechra to sell Strangvac in the country. The vaccine, approved for sale in the EU and other regions, aims to enhance the approach to equine strangles. Dechra, a specialist in veterinary pharmaceuticals, is excited to add Strangvac to its product range. The launch reflects Dechra's strong presence in Finland and aims to reach more veterinarians and horse owners.

Reuters·
UK
DPH
0.00%
Reuters·
UK
DPH
0.00%

Europe Dog Dewormers Market Report 2025-2030: Zoetis, Boehringer Ingelheim, Merck & Co., Dechra Pharmaceuticals, and Elanco Animal Health Dominate Shares

The "Europe Dog Dewormers Market Size, Share & Trends Analysis Report, 2025-2030" indicates that the market is projected to reach USD 376.7 million by 2030, growing at a CAGR of 7.76%. Key drivers include an increasing canine population and rising pet ownership expenditures. The oral administration segment is expected to grow at the highest rate, while prescription products dominate market share. The UK market is particularly strong due to improved regulatory guidelines. Major players include Zoetis, Boehringer Ingelheim, and Merck & Co.

GlobeNewswire·
US
ZTS
-0.28%
US
MRK
-0.01%
UK
DPH
0.00%
GlobeNewswire·
US
ZTS
-0.28%
US
MRK
-0.01%
UK
DPH
0.00%